IBC's 5th Annual International Conference on Angiogenesis: Novel Therapeutic Development March 22-23, 1999 -- The Fairmont Copley Plaza Hotel -- Boston, MA
BOSTON--(BW HealthWire)--Jan. 12, 1999--In an effort to share the most recent progress from ongoing angiogenesis research and clinical trials, the worlds' leading investigators will gather at IBC's 5th Annual International Conference on Angiogenesis in Boston, MA on March 22-23, 1999. New breakthroughs have given tremendous hope to the millions affected by cancer, cardiovascular disease, and several other medical conditions for which both agonists and antagonists of angiogenesis have promising therapeutic potential.
This year's program features TWO KEYNOTE PRESENTATIONS, including "Therapeutic Angiogenesis: Latest Findings and Implications" by Jeffrey M. Isner, MD (St. Elizabeth's Medical Center, Boston, MA) and "Integrins Signaling During Angiogenesis: Therapeutic Implications" by David A. Cheresh, PhD (The Scripps Research Institute, La Jolla, CA). In-depth coverage of the latest mechanisms, growth factors, inhibitors, receptors and clinical trial updates will also be discussed.
Leading organizations presenting new data include: Harvard Medical School, Children's Hospital (Boston), NIH, NIDCR, Entremed, Scios, Genentech, Abbot Laboratories, NeXstar Pharmaceuticals, DuPont Merck, Agouron Pharmaceuticals, Zeneca Pharmaceuticals, Ribozyme Pharmaceuticals, Regeneron Pharmaceuticals, and Lilly Research Laboratories. For detailed conference information, or to register, please visit the Angiogenesis website at ibcusa.com.
CONTACT:
IBC USA Conferences
Jeffrey Levinson, (508) 481-6400 ext. 632
jlevinson@ibcusa.com |
